Besides Wall Street's top-and-bottom-line estimates for Humana (HUM), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the ...

Humana Inc. (NYSE:HUM) saw its share price drop to a 52-week low of $212.33, reflecting a steep 42.3% decline over the past ...

Humana’s worsening fortunes have been a bellwether for the industry, as it has struggled with rising medical costs and ...

Humana faces real challenges like falling Medicare star ratings, shrinking margins, and tough competition. Click here to read ...

The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here ...

Analysts have recently evaluated Humana and provided 12-month price targets. The average target is $280.75, accompanied by a ...

It’s a significant loss for the insurer, which sued the government late last year after its star ratings plummeted for 2025.

Revenue Growth: Over the 3M period, Humana showcased positive performance, achieving a revenue growth rate of 10.4% as of 31 December, 2024.

Humana could face $1 billion to $3 billion in losses next year, with the star ratings drop in its Medicare Advantage program.

This stock's P/B looks attractive against its industry's average P/B of 2.20. Within the past 52 weeks, HUM's P/B has been as high as 2.91 and as low as 1.52, with a median of 1.93.